These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21116710)

  • 21. A 10-year follow-up of a patient affected by myotonic dystrophy type 1 with implantable cardioverter-defibrillator implanted for secondary prevention.
    De Ambroggi G; Ali H; Cappato R; Sansone VA; De Ambroggi L
    J Cardiovasc Med (Hagerstown); 2020 Feb; 21(2):150-152. PubMed ID: 31490228
    [No Abstract]   [Full Text] [Related]  

  • 22. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.
    Probst V; Boveda S; Sadoul N; Marquié C; Chauvin M; Mondoly P; Gras D; Jacon P; Defaye P; Leclercq C; Anselme F
    Arch Cardiovasc Dis; 2020 May; 113(5):359-366. PubMed ID: 32334981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac implantable electronic device and vascular access: Strategies to overcome problems.
    Kusztal M; Nowak K
    J Vasc Access; 2018 Nov; 19(6):521-527. PubMed ID: 29552930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study.
    El-Chami MF; Burke MC; Herre JM; Shah MH; Sadhu A; Niebauer MJ; Kutalek SP; Carter N; Gold MR
    Heart Rhythm; 2020 Sep; 17(9):1566-1574. PubMed ID: 32376304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction.
    Goldenberg I; Mor T; Nof E; Younis A; Berkovitch A; Rosso R; Barsheshet A; Suleiman M; Beinart R
    Europace; 2019 Mar; 21(3):459-464. PubMed ID: 30689821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The wearable cardioverter-defibrillator: current technology and evolving indications.
    Reek S; Burri H; Roberts PR; Perings C; Epstein AE; Klein HU; ; Lip G; Gorenek B; Sticherling C; Fauchier L; Goette A; Jung W; Vos MA; Brignole M; Elsner C; Dan GA; Marin F; Boriani G; Lane D; Blomström-Lundqvist C; Savelieva I
    Europace; 2017 Mar; 19(3):335-345. PubMed ID: 27702851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular scar burden specifies the potential for ventricular arrhythmogenesis: an LGE-CMR study.
    Scott PA; Rosengarten JA; Murday DC; Peebles CR; Harden SP; Curzen NP; Morgan JM
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):430-6. PubMed ID: 23210601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single chamber implantable cardioverter defibrillator compared to dual chamber implantable cardioverter defibrillator: less is more! Data from the German Device Registry.
    Bogossian H; Frommeyer G; Hochadel M; Ince H; Spitzer SG; Eckardt L; Maier SKG; Kleemann T; Brachmann J; Stellbrink C; Gonska BD; Kääb S; Senges J; Lemke B
    Clin Res Cardiol; 2020 Jul; 109(7):911-917. PubMed ID: 31823040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sudden death mortality in implantable cardioverter defibrillator patients.
    Gross J; Zilo P; Ferrick K; Fisher JD; Furman S
    Pacing Clin Electrophysiol; 1991 Feb; 14(2 Pt 2):250-4. PubMed ID: 1706833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is mechanical dispersion a raven of ventricular arrhythmias?
    Zoghbi WA; Narula J
    JACC Cardiovasc Imaging; 2010 Mar; 3(3):330-1. PubMed ID: 20223434
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients.
    Link MS; Sullivan RM; Olshansky B; Cannom D; Berul CI; Hauser RG; Heidbuchel H; Jordaens L; Krahn AD; Morgan J; Patton KK; Saarel EV; Wilkoff BL; Li F; Dziura J; Brandt C; Barth C; Lampert R
    Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009344. PubMed ID: 33724879
    [No Abstract]   [Full Text] [Related]  

  • 35. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arrhythmic risk stratification in non-ischemic dilated cardiomyopathy: Where do we stand after DANISH?
    Dilaveris P; Antoniou CK; Gatzoulis KA
    Trends Cardiovasc Med; 2017 Nov; 27(8):542-555. PubMed ID: 28709811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left Ventricular Entropy Is a Novel Predictor of Arrhythmic Events in Patients With Dilated Cardiomyopathy Receiving Defibrillators for Primary Prevention.
    Muthalaly RG; Kwong RY; John RM; van der Geest RJ; Tao Q; Schaeffer B; Tanigawa S; Nakamura T; Kaneko K; Tedrow UB; Stevenson WG; Epstein LM; Kapur S; Zei PC; Koplan BA
    JACC Cardiovasc Imaging; 2019 Jul; 12(7 Pt 1):1177-1184. PubMed ID: 30121262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study.
    Gunten SV; Theuns DA; Kühne M; Reichlin T; Sticherling C; Schaer B
    Cardiol J; 2019; 26(6):711-716. PubMed ID: 30484267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
    Tan VH; Wilton SB; Kuriachan V; Sumner GL; Exner DV
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):164-70. PubMed ID: 24446023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.